nodes	percent_of_prediction	percent_of_DWPC	metapath
Raloxifene—CYP19A1—semen—cervical cancer	0.0742	0.0898	CbGeAlD
Raloxifene—EBP—uterine cervix—cervical cancer	0.0494	0.0598	CbGeAlD
Raloxifene—EBP—uterus—cervical cancer	0.0411	0.0498	CbGeAlD
Raloxifene—EBP—female reproductive system—cervical cancer	0.037	0.0448	CbGeAlD
Raloxifene—ESR2—epithelium—cervical cancer	0.0173	0.021	CbGeAlD
Raloxifene—ESR2—uterine cervix—cervical cancer	0.0172	0.0208	CbGeAlD
Raloxifene—AOX1—uterine cervix—cervical cancer	0.0165	0.02	CbGeAlD
Raloxifene—ESR2—renal system—cervical cancer	0.0161	0.0195	CbGeAlD
Raloxifene—AOX1—decidua—cervical cancer	0.0158	0.0191	CbGeAlD
Raloxifene—ESR2—endometrium—cervical cancer	0.0155	0.0188	CbGeAlD
Raloxifene—AOX1—renal system—cervical cancer	0.0155	0.0187	CbGeAlD
Raloxifene—AOX1—endometrium—cervical cancer	0.015	0.0181	CbGeAlD
Raloxifene—AOX1—mammalian vulva—cervical cancer	0.0145	0.0175	CbGeAlD
Raloxifene—ESR2—uterus—cervical cancer	0.0143	0.0173	CbGeAlD
Raloxifene—AOX1—uterus—cervical cancer	0.0138	0.0167	CbGeAlD
Raloxifene—SIGMAR1—uterine cervix—cervical cancer	0.0133	0.0161	CbGeAlD
Raloxifene—HTR2B—uterine cervix—cervical cancer	0.0133	0.0161	CbGeAlD
Raloxifene—ESR2—female reproductive system—cervical cancer	0.0129	0.0156	CbGeAlD
Raloxifene—SIGMAR1—decidua—cervical cancer	0.0127	0.0154	CbGeAlD
Raloxifene—HTR2B—decidua—cervical cancer	0.0127	0.0153	CbGeAlD
Raloxifene—AOX1—female reproductive system—cervical cancer	0.0124	0.015	CbGeAlD
Raloxifene—CYP19A1—endometrium—cervical cancer	0.0123	0.0148	CbGeAlD
Raloxifene—SIGMAR1—endometrium—cervical cancer	0.012	0.0146	CbGeAlD
Raloxifene—HTR2B—endometrium—cervical cancer	0.012	0.0145	CbGeAlD
Raloxifene—ESR1—epithelium—cervical cancer	0.0119	0.0144	CbGeAlD
Raloxifene—ESR1—uterine cervix—cervical cancer	0.0118	0.0143	CbGeAlD
Raloxifene—ESR2—female gonad—cervical cancer	0.0117	0.0142	CbGeAlD
Raloxifene—SIGMAR1—mammalian vulva—cervical cancer	0.0117	0.0141	CbGeAlD
Raloxifene—ESR2—vagina—cervical cancer	0.0116	0.0141	CbGeAlD
Raloxifene—CYP19A1—uterus—cervical cancer	0.0113	0.0137	CbGeAlD
Raloxifene—AOX1—female gonad—cervical cancer	0.0113	0.0137	CbGeAlD
Raloxifene—ESR1—decidua—cervical cancer	0.0112	0.0136	CbGeAlD
Raloxifene—AOX1—vagina—cervical cancer	0.0112	0.0136	CbGeAlD
Raloxifene—SIGMAR1—uterus—cervical cancer	0.0111	0.0134	CbGeAlD
Raloxifene—HTR2B—uterus—cervical cancer	0.0111	0.0134	CbGeAlD
Raloxifene—ESR1—renal system—cervical cancer	0.011	0.0133	CbGeAlD
Raloxifene—ESR1—endometrium—cervical cancer	0.0106	0.0129	CbGeAlD
Raloxifene—CYP19A1—female reproductive system—cervical cancer	0.0101	0.0123	CbGeAlD
Raloxifene—HTR2B—female reproductive system—cervical cancer	0.00996	0.0121	CbGeAlD
Raloxifene—ESR1—uterus—cervical cancer	0.00981	0.0119	CbGeAlD
Raloxifene—CYP19A1—female gonad—cervical cancer	0.00924	0.0112	CbGeAlD
Raloxifene—SIGMAR1—female gonad—cervical cancer	0.00908	0.011	CbGeAlD
Raloxifene—CYP2C8—renal system—cervical cancer	0.00907	0.011	CbGeAlD
Raloxifene—SIGMAR1—vagina—cervical cancer	0.00902	0.0109	CbGeAlD
Raloxifene—HTR2B—vagina—cervical cancer	0.009	0.0109	CbGeAlD
Raloxifene—ESR1—female reproductive system—cervical cancer	0.00882	0.0107	CbGeAlD
Raloxifene—CYP2C8—endometrium—cervical cancer	0.00877	0.0106	CbGeAlD
Raloxifene—Neuralgia—Topotecan—cervical cancer	0.00849	0.0996	CcSEcCtD
Raloxifene—CYP2B6—renal system—cervical cancer	0.00814	0.00985	CbGeAlD
Raloxifene—ESR1—female gonad—cervical cancer	0.00803	0.00972	CbGeAlD
Raloxifene—ESR1—vagina—cervical cancer	0.00798	0.00966	CbGeAlD
Raloxifene—ESR2—lymph node—cervical cancer	0.00753	0.00912	CbGeAlD
Raloxifene—CYP2C8—female reproductive system—cervical cancer	0.00727	0.0088	CbGeAlD
Raloxifene—AOX1—lymph node—cervical cancer	0.00725	0.00878	CbGeAlD
Raloxifene—CYP2C8—vagina—cervical cancer	0.00657	0.00796	CbGeAlD
Raloxifene—CYP2B6—female reproductive system—cervical cancer	0.00652	0.00789	CbGeAlD
Raloxifene—CYP3A4—renal system—cervical cancer	0.00615	0.00744	CbGeAlD
Raloxifene—ESR2—Validated nuclear estrogen receptor alpha network—POU4F1—cervical cancer	0.0061	0.0688	CbGpPWpGaD
Raloxifene—CYP19A1—lymph node—cervical cancer	0.00594	0.00719	CbGeAlD
Raloxifene—Pulmonary embolism—Topotecan—cervical cancer	0.0059	0.0692	CcSEcCtD
Raloxifene—CYP2B6—vagina—cervical cancer	0.00589	0.00714	CbGeAlD
Raloxifene—SIGMAR1—lymph node—cervical cancer	0.00584	0.00707	CbGeAlD
Raloxifene—HTR2B—lymph node—cervical cancer	0.00582	0.00705	CbGeAlD
Raloxifene—AOX1—Tryptophan metabolism—UBE3A—cervical cancer	0.00557	0.0629	CbGpPWpGaD
Raloxifene—ESR1—lymph node—cervical cancer	0.00516	0.00625	CbGeAlD
Raloxifene—CYP3A4—female reproductive system—cervical cancer	0.00492	0.00596	CbGeAlD
Raloxifene—ESR2—Nuclear Receptors—RARB—cervical cancer	0.00486	0.0548	CbGpPWpGaD
Raloxifene—HTR6—Amine ligand-binding receptors—TAAR6—cervical cancer	0.00484	0.0546	CbGpPWpGaD
Raloxifene—HTR2B—Amine ligand-binding receptors—TAAR6—cervical cancer	0.00442	0.0498	CbGpPWpGaD
Raloxifene—Aspartate aminotransferase increased—Topotecan—cervical cancer	0.00386	0.0452	CcSEcCtD
Raloxifene—ESR2—Nuclear Receptor transcription pathway—RARB—cervical cancer	0.00384	0.0433	CbGpPWpGaD
Raloxifene—Weight increased—Topotecan—cervical cancer	0.00337	0.0395	CcSEcCtD
Raloxifene—Pneumonia—Topotecan—cervical cancer	0.00332	0.0389	CcSEcCtD
Raloxifene—Sweating—Topotecan—cervical cancer	0.00316	0.0371	CcSEcCtD
Raloxifene—ESR1—Validated nuclear estrogen receptor alpha network—POU4F1—cervical cancer	0.00307	0.0347	CbGpPWpGaD
Raloxifene—Rhinitis—Topotecan—cervical cancer	0.00297	0.0348	CcSEcCtD
Raloxifene—Hypoaesthesia—Topotecan—cervical cancer	0.00295	0.0346	CcSEcCtD
Raloxifene—Pharyngitis—Topotecan—cervical cancer	0.00294	0.0345	CcSEcCtD
Raloxifene—CYP19A1—Tryptophan metabolism—UBE3A—cervical cancer	0.00288	0.0325	CbGpPWpGaD
Raloxifene—Angiopathy—Topotecan—cervical cancer	0.00269	0.0315	CcSEcCtD
Raloxifene—ESR1—Regulation of nuclear SMAD2/3 signaling—PIAS3—cervical cancer	0.00255	0.0287	CbGpPWpGaD
Raloxifene—Muscle spasms—Topotecan—cervical cancer	0.00248	0.0291	CcSEcCtD
Raloxifene—ESR1—Nuclear Receptors—RARB—cervical cancer	0.00245	0.0276	CbGpPWpGaD
Raloxifene—Cough—Topotecan—cervical cancer	0.00225	0.0264	CcSEcCtD
Raloxifene—Myalgia—Topotecan—cervical cancer	0.0022	0.0257	CcSEcCtD
Raloxifene—Chest pain—Topotecan—cervical cancer	0.0022	0.0257	CcSEcCtD
Raloxifene—Arthralgia—Topotecan—cervical cancer	0.0022	0.0257	CcSEcCtD
Raloxifene—Unspecified disorder of skin and subcutaneous tissue—Topotecan—cervical cancer	0.00218	0.0256	CcSEcCtD
Raloxifene—Infection—Topotecan—cervical cancer	0.00209	0.0245	CcSEcCtD
Raloxifene—Nervous system disorder—Topotecan—cervical cancer	0.00206	0.0242	CcSEcCtD
Raloxifene—Thrombocytopenia—Topotecan—cervical cancer	0.00206	0.0242	CcSEcCtD
Raloxifene—Skin disorder—Topotecan—cervical cancer	0.00204	0.024	CcSEcCtD
Raloxifene—Hyperhidrosis—Topotecan—cervical cancer	0.00203	0.0239	CcSEcCtD
Raloxifene—HTR6—G alpha (s) signalling events—TAAR6—cervical cancer	0.002	0.0225	CbGpPWpGaD
Raloxifene—ESR1—Nuclear Receptor transcription pathway—RARB—cervical cancer	0.00194	0.0218	CbGpPWpGaD
Raloxifene—CYP2B6—Nuclear Receptors in Lipid Metabolism and Toxicity—RARB—cervical cancer	0.00192	0.0217	CbGpPWpGaD
Raloxifene—Musculoskeletal discomfort—Topotecan—cervical cancer	0.00192	0.0225	CcSEcCtD
Raloxifene—ESR1—Regulation of Telomerase—UBE3A—cervical cancer	0.00189	0.0213	CbGpPWpGaD
Raloxifene—Dyspepsia—Topotecan—cervical cancer	0.00185	0.0217	CcSEcCtD
Raloxifene—Gastrointestinal disorder—Topotecan—cervical cancer	0.00182	0.0213	CcSEcCtD
Raloxifene—Pain—Topotecan—cervical cancer	0.0018	0.0211	CcSEcCtD
Raloxifene—Gastrointestinal pain—Topotecan—cervical cancer	0.00172	0.0202	CcSEcCtD
Raloxifene—Abdominal pain—Topotecan—cervical cancer	0.00166	0.0195	CcSEcCtD
Raloxifene—Body temperature increased—Topotecan—cervical cancer	0.00166	0.0195	CcSEcCtD
Raloxifene—Diarrhoea—Topotecan—cervical cancer	0.00144	0.0169	CcSEcCtD
Raloxifene—Dizziness—Topotecan—cervical cancer	0.00139	0.0163	CcSEcCtD
Raloxifene—ESR1—Estrogen Receptor Pathway—STAT3—cervical cancer	0.00137	0.0155	CbGpPWpGaD
Raloxifene—Vomiting—Topotecan—cervical cancer	0.00134	0.0157	CcSEcCtD
Raloxifene—ESR2—Integrated Pancreatic Cancer Pathway—RARB—cervical cancer	0.00134	0.0151	CbGpPWpGaD
Raloxifene—Rash—Topotecan—cervical cancer	0.00133	0.0156	CcSEcCtD
Raloxifene—Dermatitis—Topotecan—cervical cancer	0.00133	0.0155	CcSEcCtD
Raloxifene—Headache—Topotecan—cervical cancer	0.00132	0.0155	CcSEcCtD
Raloxifene—AOX1—Defective AMN causes hereditary megaloblastic anemia 1—MTHFR—cervical cancer	0.0013	0.0147	CbGpPWpGaD
Raloxifene—Nausea—Topotecan—cervical cancer	0.00125	0.0147	CcSEcCtD
Raloxifene—CYP19A1—FSH signaling pathway—MTOR—cervical cancer	0.00111	0.0125	CbGpPWpGaD
Raloxifene—HTR6—Class A/1 (Rhodopsin-like receptors)—TAAR6—cervical cancer	0.000952	0.0107	CbGpPWpGaD
Raloxifene—ESR1—ATF-2 transcription factor network—HES1—cervical cancer	0.000936	0.0106	CbGpPWpGaD
Raloxifene—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—RARB—cervical cancer	0.000873	0.00985	CbGpPWpGaD
Raloxifene—HTR2B—Class A/1 (Rhodopsin-like receptors)—TAAR6—cervical cancer	0.000869	0.0098	CbGpPWpGaD
Raloxifene—ESR2—SIDS Susceptibility Pathways—HES1—cervical cancer	0.000853	0.00962	CbGpPWpGaD
Raloxifene—CYP3A4—Tryptophan metabolism—UBE3A—cervical cancer	0.000841	0.00949	CbGpPWpGaD
Raloxifene—ESR1—Regulation of Telomerase—TERT—cervical cancer	0.000732	0.00826	CbGpPWpGaD
Raloxifene—HTR6—GPCR ligand binding—TAAR6—cervical cancer	0.000725	0.00817	CbGpPWpGaD
Raloxifene—ESR1—LKB1 signaling events—MTOR—cervical cancer	0.000682	0.00769	CbGpPWpGaD
Raloxifene—ESR1—Integrated Pancreatic Cancer Pathway—RARB—cervical cancer	0.000673	0.0076	CbGpPWpGaD
Raloxifene—ESR2—Generic Transcription Pathway—RARB—cervical cancer	0.000663	0.00748	CbGpPWpGaD
Raloxifene—HTR2B—GPCR ligand binding—TAAR6—cervical cancer	0.000661	0.00746	CbGpPWpGaD
Raloxifene—EBP—Metabolism—CA9—cervical cancer	0.000574	0.00648	CbGpPWpGaD
Raloxifene—HTR6—GPCR ligand binding—WNT2—cervical cancer	0.000566	0.00638	CbGpPWpGaD
Raloxifene—HTR2B—GPCR ligand binding—WNT2—cervical cancer	0.000516	0.00582	CbGpPWpGaD
Raloxifene—ESR2—Integrated Pancreatic Cancer Pathway—CASP8—cervical cancer	0.000499	0.00563	CbGpPWpGaD
Raloxifene—ESR1—Signaling mediated by p38-alpha and p38-beta—TP53—cervical cancer	0.000474	0.00535	CbGpPWpGaD
Raloxifene—ESR1—Regulation of Telomerase—MTOR—cervical cancer	0.000473	0.00533	CbGpPWpGaD
Raloxifene—ESR1—Aryl Hydrocarbon Receptor—EGFR—cervical cancer	0.000454	0.00512	CbGpPWpGaD
Raloxifene—ESR2—SIDS Susceptibility Pathways—CASP3—cervical cancer	0.000444	0.005	CbGpPWpGaD
Raloxifene—ESR2—Generic Transcription Pathway—NOTCH2—cervical cancer	0.000439	0.00496	CbGpPWpGaD
Raloxifene—ESR1—Leptin signaling pathway—MTOR—cervical cancer	0.000437	0.00493	CbGpPWpGaD
Raloxifene—HTR6—GPCR ligand binding—WNT5A—cervical cancer	0.000429	0.00484	CbGpPWpGaD
Raloxifene—ESR2—SIDS Susceptibility Pathways—CTNNB1—cervical cancer	0.000428	0.00482	CbGpPWpGaD
Raloxifene—HTR6—GPCR downstream signaling—TAAR6—cervical cancer	0.000409	0.00462	CbGpPWpGaD
Raloxifene—ESR1—AP-1 transcription factor network—CTNNB1—cervical cancer	0.000409	0.00462	CbGpPWpGaD
Raloxifene—AOX1—Disease—WNT2—cervical cancer	0.000402	0.00454	CbGpPWpGaD
Raloxifene—ESR1—LKB1 signaling events—TP53—cervical cancer	0.000402	0.00454	CbGpPWpGaD
Raloxifene—HTR2B—GPCR ligand binding—WNT5A—cervical cancer	0.000391	0.00441	CbGpPWpGaD
Raloxifene—ESR2—Integrated Pancreatic Cancer Pathway—CASP3—cervical cancer	0.000377	0.00426	CbGpPWpGaD
Raloxifene—HTR2B—GPCR downstream signaling—TAAR6—cervical cancer	0.000374	0.00422	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—TAAR6—cervical cancer	0.000372	0.00419	CbGpPWpGaD
Raloxifene—ESR2—Integrated Pancreatic Cancer Pathway—CTNNB1—cervical cancer	0.000364	0.0041	CbGpPWpGaD
Raloxifene—ESR1—Signaling by ERBB4—FGFR3—cervical cancer	0.000353	0.00398	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—TAAR6—cervical cancer	0.000339	0.00383	CbGpPWpGaD
Raloxifene—CYP19A1—Integrated Breast Cancer Pathway—CASP8—cervical cancer	0.000339	0.00382	CbGpPWpGaD
Raloxifene—ESR1—Leptin signaling pathway—STAT3—cervical cancer	0.000338	0.00381	CbGpPWpGaD
Raloxifene—ESR1—Generic Transcription Pathway—RARB—cervical cancer	0.000334	0.00377	CbGpPWpGaD
Raloxifene—ESR1—Regulation of Telomerase—EGFR—cervical cancer	0.000332	0.00374	CbGpPWpGaD
Raloxifene—ESR2—Gene Expression—RARB—cervical cancer	0.000319	0.0036	CbGpPWpGaD
Raloxifene—AOX1—Metabolism—CA9—cervical cancer	0.000318	0.00359	CbGpPWpGaD
Raloxifene—AOX1—Disease—WNT5A—cervical cancer	0.000305	0.00344	CbGpPWpGaD
Raloxifene—ESR1—Integrated Breast Cancer Pathway—CASP8—cervical cancer	0.000303	0.00342	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—WNT2—cervical cancer	0.00029	0.00327	CbGpPWpGaD
Raloxifene—ESR2—Integrated Pancreatic Cancer Pathway—EGFR—cervical cancer	0.000288	0.00325	CbGpPWpGaD
Raloxifene—HTR6—GPCR downstream signaling—AKAP13—cervical cancer	0.000281	0.00317	CbGpPWpGaD
Raloxifene—CYP19A1—Integrated Breast Cancer Pathway—MTOR—cervical cancer	0.000279	0.00315	CbGpPWpGaD
Raloxifene—ESR1—AP-1 transcription factor network—TP53—cervical cancer	0.000272	0.00307	CbGpPWpGaD
Raloxifene—ESR2—Generic Transcription Pathway—NOTCH1—cervical cancer	0.000272	0.00307	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—WNT2—cervical cancer	0.000265	0.00299	CbGpPWpGaD
Raloxifene—CYP19A1—Integrated Breast Cancer Pathway—CASP3—cervical cancer	0.000256	0.00289	CbGpPWpGaD
Raloxifene—HTR2B—GPCR downstream signaling—AKAP13—cervical cancer	0.000256	0.00289	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—AKAP13—cervical cancer	0.000255	0.00287	CbGpPWpGaD
Raloxifene—ESR1—Integrated Pancreatic Cancer Pathway—CASP8—cervical cancer	0.000251	0.00284	CbGpPWpGaD
Raloxifene—ESR1—Integrated Breast Cancer Pathway—MTOR—cervical cancer	0.00025	0.00282	CbGpPWpGaD
Raloxifene—ESR1—Signaling by ERBB4—MTOR—cervical cancer	0.000248	0.0028	CbGpPWpGaD
Raloxifene—CYP19A1—Integrated Breast Cancer Pathway—CTNNB1—cervical cancer	0.000247	0.00279	CbGpPWpGaD
Raloxifene—ESR2—Integrated Pancreatic Cancer Pathway—TP53—cervical cancer	0.000242	0.00273	CbGpPWpGaD
Raloxifene—EBP—Metabolism—MTHFR—cervical cancer	0.000233	0.00263	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—AKAP13—cervical cancer	0.000233	0.00262	CbGpPWpGaD
Raloxifene—ESR1—Integrated Breast Cancer Pathway—CASP3—cervical cancer	0.00023	0.00259	CbGpPWpGaD
Raloxifene—ESR1—Generic Transcription Pathway—NOTCH2—cervical cancer	0.000222	0.0025	CbGpPWpGaD
Raloxifene—ESR1—Integrated Breast Cancer Pathway—CTNNB1—cervical cancer	0.000221	0.0025	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—WNT5A—cervical cancer	0.00022	0.00248	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—TAAR6—cervical cancer	0.00022	0.00248	CbGpPWpGaD
Raloxifene—ESR2—Gene Expression—NOTCH2—cervical cancer	0.000212	0.00239	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—WNT5A—cervical cancer	0.000201	0.00227	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—TAAR6—cervical cancer	0.000201	0.00226	CbGpPWpGaD
Raloxifene—CYP19A1—Integrated Breast Cancer Pathway—EGFR—cervical cancer	0.000196	0.00221	CbGpPWpGaD
Raloxifene—ESR1—Integrated Pancreatic Cancer Pathway—CASP3—cervical cancer	0.00019	0.00215	CbGpPWpGaD
Raloxifene—ESR1—Integrated Pancreatic Cancer Pathway—CTNNB1—cervical cancer	0.000183	0.00207	CbGpPWpGaD
Raloxifene—AOX1—Disease—HES1—cervical cancer	0.000175	0.00198	CbGpPWpGaD
Raloxifene—ESR1—Integrated Breast Cancer Pathway—EGFR—cervical cancer	0.000175	0.00198	CbGpPWpGaD
Raloxifene—ESR1—Signaling by ERBB4—EGFR—cervical cancer	0.000174	0.00197	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—WNT2—cervical cancer	0.000171	0.00193	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—TAAR6—cervical cancer	0.000167	0.00188	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—CA9—cervical cancer	0.000164	0.00186	CbGpPWpGaD
Raloxifene—CYP19A1—Integrated Breast Cancer Pathway—TP53—cervical cancer	0.000164	0.00186	CbGpPWpGaD
Raloxifene—ESR1—Gene Expression—RARB—cervical cancer	0.000161	0.00182	CbGpPWpGaD
Raloxifene—HTR2B—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—cervical cancer	0.000159	0.00179	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—WNT2—cervical cancer	0.000157	0.00177	CbGpPWpGaD
Raloxifene—AOX1—Disease—MTHFR—cervical cancer	0.000154	0.00174	CbGpPWpGaD
Raloxifene—AOX1—Disease—TERT—cervical cancer	0.000154	0.00173	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—AKAP13—cervical cancer	0.000151	0.0017	CbGpPWpGaD
Raloxifene—ESR1—Integrated Breast Cancer Pathway—TP53—cervical cancer	0.000147	0.00166	CbGpPWpGaD
Raloxifene—ESR1—Integrated Pancreatic Cancer Pathway—EGFR—cervical cancer	0.000145	0.00164	CbGpPWpGaD
Raloxifene—AOX1—Disease—FGFR3—cervical cancer	0.000141	0.00159	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—AKAP13—cervical cancer	0.000137	0.00155	CbGpPWpGaD
Raloxifene—ESR1—Generic Transcription Pathway—NOTCH1—cervical cancer	0.000137	0.00155	CbGpPWpGaD
Raloxifene—AOX1—Disease—NOTCH1—cervical cancer	0.000132	0.00149	CbGpPWpGaD
Raloxifene—ESR2—Gene Expression—NOTCH1—cervical cancer	0.000131	0.00148	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—WNT2—cervical cancer	0.00013	0.00147	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—WNT5A—cervical cancer	0.00013	0.00147	CbGpPWpGaD
Raloxifene—AOX1—Metabolism—MTHFR—cervical cancer	0.000129	0.00146	CbGpPWpGaD
Raloxifene—ESR1—Integrated Pancreatic Cancer Pathway—TP53—cervical cancer	0.000122	0.00138	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—WNT5A—cervical cancer	0.000119	0.00134	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—AKAP13—cervical cancer	0.000114	0.00129	CbGpPWpGaD
Raloxifene—ESR1—Gene Expression—NOTCH2—cervical cancer	0.000107	0.0012	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—CA9—cervical cancer	0.000106	0.00119	CbGpPWpGaD
Raloxifene—AOX1—Disease—MTOR—cervical cancer	9.92e-05	0.00112	CbGpPWpGaD
Raloxifene—AOX1—Disease—CD4—cervical cancer	9.9e-05	0.00112	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—WNT5A—cervical cancer	9.88e-05	0.00111	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—NOTCH2—cervical cancer	9.12e-05	0.00103	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—CA9—cervical cancer	8.94e-05	0.00101	CbGpPWpGaD
Raloxifene—AOX1—Disease—CTNNB1—cervical cancer	8.8e-05	0.000992	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—NOTCH2—cervical cancer	8.33e-05	0.000939	CbGpPWpGaD
Raloxifene—AOX1—Disease—STAT3—cervical cancer	7.67e-05	0.000865	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—HES1—cervical cancer	7.48e-05	0.000844	CbGpPWpGaD
Raloxifene—AOX1—Disease—EGFR—cervical cancer	6.97e-05	0.000786	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—NOTCH2—cervical cancer	6.94e-05	0.000782	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—HES1—cervical cancer	6.83e-05	0.00077	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—MTHFR—cervical cancer	6.68e-05	0.000753	CbGpPWpGaD
Raloxifene—ESR1—Gene Expression—NOTCH1—cervical cancer	6.6e-05	0.000745	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—TERT—cervical cancer	6.55e-05	0.000739	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—FGFR3—cervical cancer	6.01e-05	0.000678	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—TERT—cervical cancer	5.98e-05	0.000675	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—HES1—cervical cancer	5.69e-05	0.000641	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—NOTCH1—cervical cancer	5.65e-05	0.000637	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—FGFR3—cervical cancer	5.49e-05	0.000619	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—NOTCH1—cervical cancer	5.15e-05	0.000581	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—EGFR—cervical cancer	5.03e-05	0.000567	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—TERT—cervical cancer	4.98e-05	0.000562	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—CA9—cervical cancer	4.8e-05	0.000542	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—EGFR—cervical cancer	4.59e-05	0.000518	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—FGFR3—cervical cancer	4.57e-05	0.000516	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—NOTCH1—cervical cancer	4.29e-05	0.000484	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—MTHFR—cervical cancer	4.29e-05	0.000484	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—MTOR—cervical cancer	4.23e-05	0.000477	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—CASP3—cervical cancer	3.89e-05	0.000439	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—MTOR—cervical cancer	3.86e-05	0.000436	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—CTNNB1—cervical cancer	3.75e-05	0.000423	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—MTHFR—cervical cancer	3.63e-05	0.000409	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—CASP3—cervical cancer	3.55e-05	0.000401	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—CTNNB1—cervical cancer	3.42e-05	0.000386	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—STAT3—cervical cancer	3.27e-05	0.000369	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—MTOR—cervical cancer	3.22e-05	0.000363	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—STAT3—cervical cancer	2.98e-05	0.000337	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—EGFR—cervical cancer	2.97e-05	0.000335	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—CASP3—cervical cancer	2.96e-05	0.000334	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—CTNNB1—cervical cancer	2.85e-05	0.000322	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—EGFR—cervical cancer	2.71e-05	0.000306	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—TP53—cervical cancer	2.49e-05	0.000281	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—STAT3—cervical cancer	2.49e-05	0.00028	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—TP53—cervical cancer	2.28e-05	0.000257	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—EGFR—cervical cancer	2.26e-05	0.000255	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—MTHFR—cervical cancer	1.95e-05	0.00022	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—TP53—cervical cancer	1.9e-05	0.000214	CbGpPWpGaD
